Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.
2.

Pharmacogenetics of chronic pain and its treatment.

Světlík S, Hronová K, Bakhouche H, Matoušková O, Slanař O.

Mediators Inflamm. 2013;2013:864319. doi: 10.1155/2013/864319. Epub 2013 May 20. Review.

3.

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene.

Trdan Lušin T, Stieger B, Marc J, Mrhar A, Trontelj J, Zavratnik A, Ostanek B.

J Transl Med. 2012 Apr 25;10:76. doi: 10.1186/1479-5876-10-76.

4.

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Roth M, Obaidat A, Hagenbuch B.

Br J Pharmacol. 2012 Mar;165(5):1260-87. doi: 10.1111/j.1476-5381.2011.01724.x. Review.

5.

Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates.

Weaver YM, Hagenbuch B.

J Membr Biol. 2010 Aug;236(3):279-90. doi: 10.1007/s00232-010-9300-3. Epub 2010 Sep 4.

6.

Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Klaassen CD, Aleksunes LM.

Pharmacol Rev. 2010 Mar;62(1):1-96. doi: 10.1124/pr.109.002014. Epub 2010 Jan 26. Review.

7.

Impact of OATP transporters on pharmacokinetics.

Kalliokoski A, Niemi M.

Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. Review.

8.

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB.

Pharmacogenet Genomics. 2007 Aug;17(8):647-56.

9.

Supplemental Content

Support Center